Dopamine Related Published Studies
Well-designed clinical trials related to Dopamine
Effect of low dose dopamine on early graft function in living unrelated kidney
donors. [2012]
Efficacy and safety of dopamine agonists in restless legs syndrome. [2012]
Pharmacokinetics and central nervous system effects of the novel dopamine D3
receptor antagonist GSK598809 and intravenous alcohol infusion at pseudo-steady
state. [2012]
Effects of donor pre-treatment with dopamine on survival after heart transplantation: a cohort study of heart transplant recipients nested in a randomized controlled multicenter trial. [2011.10.18]
Effects of working-memory training on striatal dopamine release. [2011.08.05]
Preferential D2 or preferential D3 dopamine agonists in restless legs syndrome. [2011.07.12]
Renal function after dopamine and fluid administration in patients with malignant obstructive jaundice. A prospective randomized study. [2011.06]
Cardiac valve disease and low-dose dopamine agonist therapy: an artefact of reporting bias? [2011.05]
Effect of intravenous lidocaine associated with amitriptyline on pain relief and plasma serotonin, norepinephrine, and dopamine concentrations in fibromyalgia. [2011.05]
The moderating role of the dopamine transporter 1 gene on P50 sensory gating and its modulation by nicotine. [2011.04.28]
Tinnitus control by dopamine agonist pramipexole in presbycusis patients: a randomized, placebo-controlled, double-blind study. [2011.04]
Peripheral biomarkers of cognitive response to dopamine receptor agonist treatment. [2011.04]
Dopaminergic modulation of the human reward system: a placebo-controlled dopamine depletion fMRI study. [2011.04]
The role of nutrition in the regulation of luteinizing hormone secretion by the opioidergic, dopaminergic, and serotonergic systems in female Mediterranean goats. [2011.03]
Dopaminergic stimulation enhances confidence and accuracy in seeing rapidly presented words. [2011.02.23]
The role of dopamine agonists in the treatment of depression in patients with Parkinson's disease: a systematic review. [2011.02.12]
Effects of acute dopamine-agonist treatment in restless legs syndrome on heart rate variability during sleep. [2011.01]
Dopamine versus norepinephrine in the treatment of shock. [2011]
Impact of dopamine infusion on renal function in hospitalized heart failure patients: results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial. [2010.12]
Serotonin transporters in dopamine transporter imaging: a head-to-head comparison of dopamine transporter SPECT radioligands 123I-FP-CIT and 123I-PE2I. [2010.12]
Overcoming qEEG abnormalities and reward gene deficits during protracted abstinence in male psychostimulant and polydrug abusers utilizing putative dopamine D agonist therapy: part 2. [2010.11]
Dopaminergic treatment in idiopathic restless legs syndrome: effects on subjective sleepiness. [2010.11]
Dopaminergic modulation of the default mode network in Parkinson's disease. [2010.11]
Impaired visuospatial associative memory and attention in obsessive compulsive disorder but no evidence for differential dopaminergic modulation. [2010.10]
Smoking-induced change in intrasynaptic dopamine concentration: effect of treatment for Tobacco Dependence. [2010.09.30]
Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease. [2010.09]
Increasing dopamine levels in the brain improves feedback-based procedural learning in healthy participants: an artificial-grammar-learning experiment. [2010.09]
Dopamine precursor depletion improves punishment prediction during reversal learning in healthy females but not males. [2010.08]
Dopamine, paranormal belief, and the detection of meaningful stimuli. [2010.08]
Dopamine D4 receptor gene variation moderates the efficacy of bupropion for smoking cessation. [2010.07.27]
Dopaminergic modulation of rapid reality adaptation in thinking. [2010.05.19]
Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study. [2010.05]
Pergolide treatment of cognitive deficits associated with schizotypal personality disorder: continued evidence of the importance of the dopamine system in the schizophrenia spectrum. [2010.05]
Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease. [2010.04.30]
Dopamine receptor D4 polymorphism predicts the effect of L-DOPA on gambling behavior. [2010.04.15]
Prospective association of dopamine-related polymorphisms with smoking cessation in general care. [2010.04]
The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial. [2010.04]
Efficacy and safety of dopamine versus norepinephrine in the management of septic shock. [2010.04]
Effects of nicotine on the amplitude and gating of the auditory P50 and its influence by dopamine D2 receptor gene polymorphism. [2010.03.10]
Comparison of dopamine and norepinephrine in the treatment of shock. [2010.03.04]
Polymorphisms in dopamine transporter (SLC6A3) are associated with stimulant effects of D-amphetamine: an exploratory pharmacogenetic study using healthy volunteers. [2010.03]
The effect of dopamine partial agonists on the nicotine dependency in patients with schizophrenia. [2010.03]
Memory encoding and dopamine in the aging brain: a psychopharmacological neuroimaging study. [2010.03]
Dopamine-induced changes in neural network patterns supporting aversive conditioning. [2010.02.08]
Randomized trials of dopamine agonists in restless legs syndrome: a systematic review, quality assessment, and meta-analysis. [2010.02]
A PET study examining pharmacokinetics and dopamine transporter occupancy of two long-acting formulations of methylphenidate in adults. [2010.02]
Acute dopamine and/or serotonin depletion does not modulate mismatch negativity (MMN) in healthy human participants. [2010.02]
Comparison of phenylephrine and norepinephrine in the management of dopamine-resistant septic shock. [2010.01]
Effects of a dopamine agonist on the pharmacodynamics of levodopa in Parkinson disease. [2010.01]
Dopamine cell implantation in Parkinson's disease: long-term clinical and (18)F-FDOPA PET outcomes. [2010.01]
Safety, tolerability, and pharmacokinetics of etamicastat, a novel dopamine-beta-hydroxylase inhibitor, in a rising multiple-dose study in young healthy subjects. [2010]
Dopaminergic treatment in idiopathic restless legs syndrome: effects on
subjective sleepiness. [2010]
Smoking-induced change in intrasynaptic dopamine concentration: effect of
treatment for Tobacco Dependence. [2010]
Double-blind study of pardoprunox, a new partial dopamine agonist, in early
Parkinson's disease. [2010]
Pergolide treatment of cognitive deficits associated with schizotypal personality
disorder: continued evidence of the importance of the dopamine system in the
schizophrenia spectrum. [2010]
Tolerability and safety of ropinirole versus other dopamine agonists and levodopa
in the treatment of Parkinson's disease: meta-analysis of randomized controlled
trials. [2010]
Effects of a dopamine agonist on the pharmacodynamics of levodopa in Parkinson
disease. [2010]
Dopamine cell implantation in Parkinson's disease: long-term clinical and
(18)F-FDOPA PET outcomes. [2010]
Is dopexamine superior to dopamine in the treatment of multiple trauma
patients--a prospective, double-blind, randomised study. [2010]
Dopaminergic challenges in social anxiety disorder: evidence for dopamine D3
desensitisation following successful treatment with serotonergic antidepressants. [2010]
Systematic review of the effect of dopamine receptor agonists on patient health-related quality of life. [2009.12]
Evaluation of genetic variability in the dopamine receptor D2 in relation to behavioral inhibition and impulsivity/sensation seeking: an exploratory study with d-amphetamine in healthy participants. [2009.12]
Dopaminergic modulation of amygdala activity during emotion recognition in patients with Parkinson disease. [2009.12]
The effects of lorazepam on extrastriatal dopamine D(2/3)-receptors-A double-blind randomized placebo-controlled PET study. [2009.11.30]
Absorption, disposition, metabolic fate, and elimination of the dopamine agonist rotigotine in man: administration by intravenous infusion or transdermal delivery. [2009.10]
Decreased ventilatory response to exercise by dopamine-induced inhibition of peripheral chemosensitivity. [2009.09.30]
Effects of donor pretreatment with dopamine on graft function after kidney transplantation: a randomized controlled trial. [2009.09.09]
Dopamine genes and nicotine dependence in treatment-seeking and community smokers. [2009.09]
Comparison of the effect of gonadotropin-releasing hormone agonist and dopamine receptor agonist on uterine myoma growth. Histologic, sonographic, and intra-operative changes. [2009.08]
Single dose of a dopamine agonist impairs reinforcement learning in humans: evidence from event-related potentials and computational modeling of striatal-cortical function. [2009.07]
Acute dopamine depletion with branched chain amino acids decreases auditory top-down event-related potentials in healthy subjects. [2009.06]
Striatal dopamine responses to intranasal cocaine self-administration in humans. [2009.05.15]
Dopamine D2 receptor polymorphisms and adenoma recurrence in the Polyp Prevention Trial. [2009.05.01]
Dopamine versus norepinephrine: is one better? [2009.05]
Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. [2009.05]
Dopamine and cognitive functioning in de novo subjects with Parkinson's disease: effects of pramipexole and pergolide on working memory. [2009.04]
Dopamine-related genotypes and the dose-response effect of methylphenidate on eating in attention-deficit/hyperactivity disorder youths. [2009.04]
The effects of d-amphetamine on extrastriatal dopamine D2/D3 receptors: a randomized, double-blind, placebo-controlled PET study with [11C]FLB 457 in healthy subjects. [2009.03]
Changes in psychomotor effects of L-dopa and methylphenidate after sustained dopaminergic therapy in Parkinson's disease. [2009.03]
Striatal dopamine predicts outcome-specific reversal learning and its sensitivity to dopaminergic drug administration. [2009.02.04]
Influence of domperidone on pharmacokinetics, safety and tolerability of the dopamine agonist rotigotine. [2009.02]
Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. [2009.02]
D2 dopamine receptor Taq1A polymorphism, body weight, and dietary intake in type 2 diabetes. [2009.01]
Safety and tolerability of pardoprunox, a new partial dopamine agonist, in a randomized, controlled study of patients with advanced Parkinson's disease. [2009]
The effects of withdrawal of dopaminergic medication in nursing home patients with advanced parkinsonism. [2008.11]
Basal ganglia, dopamine and temporal processing: performance on three timing tasks on and off medication in Parkinson's disease. [2008.10]
Defining the boundaries of the response of sleep leg movements to a single dose of dopamine agonist. [2008.09.01]
Dopamine and opioid gene variants are associated with increased smoking reward and reinforcement owing to negative mood. [2008.09]
Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia. [2008.08]
Induction of tolerance of dopaminergic responses in man. [2008.08]
Brain dopamine response in human opioid addiction. [2008.07]
Effects of an attachment-based intervention on daily cortisol moderated by dopamine receptor D4: a randomized control trial on 1- to 3-year-olds screened for externalizing behavior. [2008.06]
A population pharmacokinetic model of epidural lidocaine in geriatric patients: effects of low-dose dopamine. [2008.06]
The role of dopamine in alcohol self-administration in humans: individual differences. [2008.06]
Effects of selective and combined serotonin and dopamine depletion on the loudness dependence of the auditory evoked potential (LDAEP) in humans. [2008.06]
Differential effects of acute serotonin and dopamine depletion on prepulse inhibition and p50 suppression measures of sensorimotor and sensory gating in humans. [2008.06]
Enhanced dopamine release by nicotine in cigarette smokers: a double-blind, randomized, placebo-controlled pilot study. [2008.05]
The effects of acute dopamine reuptake inhibition on performance. [2008.05]
Dopamine depletion impairs frontostriatal functional connectivity during a set-shifting task. [2008.04.02]
Where dopamine meets opioids: a meta-analysis of the placebo effect in restless legs syndrome treatment studies. [2008.04]
Genetic variation in the dopamine D4 receptor (DRD4) gene and smoking cessation: follow-up of a randomised clinical trial of transdermal nicotine patch. [2008.04]
|
